EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge
- Chinnaiyan, Arul M. — University of Michigan
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Semmes, John — Eastern Virginia Medical School
- Wagner, Andrew — Beth Israel Deaconess Medical Center
- Partin, Alan W — Johns Hopkins University Department of Urology
- Grizzle, William E. — University of Alabama at Birmingham
The goal of this EDRN set-asides proposal is to carry out pre-validation studies on sarcosine as a metabolomic biomarker of prostate cancer in urine. Not only does sarcosine have potential as a marker for the early detection of prostate cancer in post-DRE urine specimens-- but since its highest levels are in metastatic disease it might have utility in predicting aggressiveness of clinically localized disease. We will also use these funds to determine if we can add additional metabolites to sarcosine in order to develop a multiplex metabolomic biomarker panel in prostate cancer. In addition to sarcosine, we have 10-12 additional candidate metabolomic biomarkers that could be developed (as seen from our preliminary global metabolite studies).
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.